A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
NCT ID: NCT06261957
Last Updated: 2025-07-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
412 participants
INTERVENTIONAL
2024-05-31
2025-09-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive
NCT06433921
A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive
NCT06433908
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
NCT06702462
A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
NCT00441441
A Study to Compare the Effects of Two Propellants in Adults With Mild Asthma
NCT05472662
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Salbutamol Test Arm
Salbutamol HFA-152a
100 μg (ex-valve) at 30-second intervals per actuation
Salbutamol Reference Arm
Salbutamol HFA-134a
100 microgram (μg) (ex-valve) at 30-second intervals per actuation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Salbutamol HFA-134a
100 microgram (μg) (ex-valve) at 30-second intervals per actuation
Salbutamol HFA-152a
100 μg (ex-valve) at 30-second intervals per actuation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Asthma for ≥ 6 months, defined as:
* Documented history of asthma, as defined by Global Initiative for Asthma (GINA) (GINA, 2023\]
* Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled corticosteroid (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist \[LAMA\]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:
* Short-Acting Beta-2-Adrenoreceptor Agonists (SABA) used as needed for asthma symptoms
* Daily maintenance low to medium dose Inhaled corticosteroid (ICS) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the 2023 GINA guidelines \[GINA, 2023\], plus Short-Acting Beta-2-Adrenoreceptor Agonists (SABA), which is anticipated to remain stable for the duration of the study.
* Daily maintenance low to medium dose ICS/ Long-acting bronchodilator (LABA) (low to medium dose ICS defined as 100-500 μg/day fluticasone propionate or equivalent as defined in the GINA guidelines \[GINA, 2023\] plus SABA, which is anticipated to remain stable for the duration of the study.
* Daily maintenance ICS/LABA/LAMA (low to medium dose ICS defined as 100-500 µg/day fluticasone propionate or equivalent as defined in the GINA guidelines \[GINA, 2023\] plus SABA, which is anticipated to remain stable for the duration of the study.
* Participants who utilize combination budesonide/formoterol as reliever therapy, whether or not this is in addition to a SABA - are not eligible for screening.
* Participants who utilize ICS/SABA combination therapy as reliever therapy, in addition to low to medium dose ICS or ICS/LABA as maintenance, are only eligible if they agree to discontinue their ICS/SABA inhaler for the duration of the study (screening through follow-up).
3. Severity of disease assessed by the investigator by baseline pre-bronchodilator Forced expiratory volume in 1 second (FEV1)
4. Asthma Control Status
* Asthma Control Questionnaire (ACQ) 6 score \<1.5 at screening
* Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:
* Deterioration of asthma-requiring the use of systemic corticosteroids (tablets, suspension or injection), for at least 3 days, OR
* An inpatient hospitalization or Emergency Department (ED) visit because of asthma, requiring systemic corticosteroids.
5. Evidence of reversibility of disease: Airway reversibility is defined as ≥12 percent (%) and ≥200 milliliter (mL) increase in FEV1 within 20 to 60 minutes following up to 4 inhalations of albuterol/salbutamol aerosol.
6. Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):
* With a documented history of reversibility (as defined above) within 2 years will meet this inclusion criterion. Pre- and post-bronchodilator measurements will still be collected at screening to characterize the degree of reversibility.
* Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.
* SABA should be withheld for ≥6 hours
* Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
7. Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
* Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.
* SABA should be withheld for ≥6 hours
* LABA- and LAMA-containing medications should be withheld for \>=24 hours for the characterization of post-bronchodilator change.
Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.
Exclusion Criteria
2. Other significant pulmonary diseases to include (but not limited to): pneumothorax, pulmonary fibrotic disease, bronchopulmonary dysplasia, chronic bronchitis, emphysema, chronic obstructive pulmonary disease, tuberculosis or other respiratory abnormalities other than asthma.
3. Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening that led to a change in asthma management, OR in the opinion of the Investigator, is expected to affect the participant's asthma status, OR the participant's ability to participate in the study.
4. Asthma Exacerbation: Any severe asthma exacerbation within 6 months prior to screening.
5. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) Biologic/immunosuppressive therapies used for the treatment of respiratory diseases during the 6 months, or 5 half-lives-whichever is longer-prior to start of the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
North Hollywood, California, United States
GSK Investigational Site
San Mateo, California, United States
GSK Investigational Site
Colorado Springs, Colorado, United States
GSK Investigational Site
Aventura, Florida, United States
GSK Investigational Site
Clearwater, Florida, United States
GSK Investigational Site
DeLand, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Naples, Florida, United States
GSK Investigational Site
Plantation, Florida, United States
GSK Investigational Site
Winter Park, Florida, United States
GSK Investigational Site
Rincon, Georgia, United States
GSK Investigational Site
Stonecrest, Georgia, United States
GSK Investigational Site
Louisville, Kentucky, United States
GSK Investigational Site
Owensboro, Kentucky, United States
GSK Investigational Site
Fall River, Massachusetts, United States
GSK Investigational Site
Minneapolis, Minnesota, United States
GSK Investigational Site
Minneota, Minnesota, United States
GSK Investigational Site
Olive Branch, Mississippi, United States
GSK Investigational Site
Columbia, Missouri, United States
GSK Investigational Site
Henderson, Nevada, United States
GSK Investigational Site
Jersey City, New Jersey, United States
GSK Investigational Site
Riverdale, New Jersey, United States
GSK Investigational Site
Brooklyn, New York, United States
GSK Investigational Site
Asheville, North Carolina, United States
GSK Investigational Site
Winston-Salem, North Carolina, United States
GSK Investigational Site
Cincinnati, Ohio, United States
GSK Investigational Site
Dublin, Ohio, United States
GSK Investigational Site
Medford, Oregon, United States
GSK Investigational Site
Philadelphia, Pennsylvania, United States
GSK Investigational Site
Pittsburgh, Pennsylvania, United States
GSK Investigational Site
Pottstown, Pennsylvania, United States
GSK Investigational Site
Rock Hill, South Carolina, United States
GSK Investigational Site
Spartanburg, South Carolina, United States
GSK Investigational Site
Union, South Carolina, United States
GSK Investigational Site
Sugar Land, Texas, United States
GSK Investigational Site
Tomball, Texas, United States
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
Buenos Aires, , Argentina
GSK Investigational Site
La Plata, , Argentina
GSK Investigational Site
Mendoza, , Argentina
GSK Investigational Site
Botany, New South Wales, Australia
GSK Investigational Site
Coffs Harbour, New South Wales, Australia
GSK Investigational Site
Kanwal, New South Wales, Australia
GSK Investigational Site
Spearwood, Western Australia, Australia
GSK Investigational Site
Ajax, Ontario, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Windsor, Ontario, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Amiens, , France
GSK Investigational Site
Argenteuil, , France
GSK Investigational Site
Cannes, , France
GSK Investigational Site
Créteil, , France
GSK Investigational Site
Poitiers, , France
GSK Investigational Site
Pontoise, , France
GSK Investigational Site
Strasbourg, , France
GSK Investigational Site
Athens, , Greece
GSK Investigational Site
Larissa, , Greece
GSK Investigational Site
Thessaloniki, , Greece
GSK Investigational Site
Cagliari, , Italy
GSK Investigational Site
Florence, , Italy
GSK Investigational Site
Foggia, , Italy
GSK Investigational Site
Milan, , Italy
GSK Investigational Site
Napoli, , Italy
GSK Investigational Site
Padua, , Italy
GSK Investigational Site
Roma, , Italy
GSK Investigational Site
Torino, , Italy
GSK Investigational Site
Tradate VA, , Italy
GSK Investigational Site
Verona, , Italy
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Iloilo City, , Philippines
GSK Investigational Site
Bialystok, , Poland
GSK Investigational Site
Bielsko-Biala, , Poland
GSK Investigational Site
Chorzów, , Poland
GSK Investigational Site
Elblag, , Poland
GSK Investigational Site
Katowice, , Poland
GSK Investigational Site
Ostrowiec Świętokrzyski, , Poland
GSK Investigational Site
Płock, , Poland
GSK Investigational Site
Tarnów, , Poland
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Barcelona, , Spain
GSK Investigational Site
Benalmádena, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Marbella, , Spain
GSK Investigational Site
Pozuelo de AlarcOn Madr, , Spain
GSK Investigational Site
Santiago de Compostela, , Spain
GSK Investigational Site
Pathum Thani, , Thailand
GSK Investigational Site
Bebington, , United Kingdom
GSK Investigational Site
Cambridgeshire, , United Kingdom
GSK Investigational Site
Corby, , United Kingdom
GSK Investigational Site
Greater Manchester, , United Kingdom
GSK Investigational Site
Guisborough, , United Kingdom
GSK Investigational Site
Hounslow, , United Kingdom
GSK Investigational Site
Rhyl, , United Kingdom
GSK Investigational Site
Uttoxeter, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-509001-76-00
Identifier Type: OTHER
Identifier Source: secondary_id
220735
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.